Search Results - "Meade, Angela"

KRAS and BRAF Mutations in Advanced Colorectal Cancer Are Associated With Poor Prognosis but Do Not Preclude Benefit From Oxaliplatin or Irinotecan: Results From the MRC FOCUS Trial by Richman, Susan D, Seymour, Matthew T, Chambers, Philip, Elliott, Faye, Daly, Catherine L, Meade, Angela M, Taylor, Graham, Barrett, Jennifer H, Quirke, Philip

“…Activating mutation of the KRAS oncogene is an established predictive biomarker for resistance to anti-epidermal growth factor receptor (anti-EGFR) therapies…”
Get full text

Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial by Maughan, Timothy S, Prof, Adams, Richard A, FRCP, Smith, Christopher G, BSc, Meade, Angela M, DPhil, Seymour, Matthew T, Prof, Wilson, Richard H, MD, Idziaszczyk, Shelley, MPhil, Harris, Rebecca, MSc, Fisher, David, MSc, Kenny, Sarah L, MSc, Kay, Edward, BA, Mitchell, Jenna K, BHSc, Madi, Ayman, MRCP, Jasani, Bharat, Prof, James, Michelle D, BSc, Bridgewater, John, MD, Kennedy, M John, MD, Claes, Bart, MSc, Lambrechts, Diether, PhD, Kaplan, Richard, Prof, Cheadle, Jeremy P, Prof

“…Summary Background In the Medical Research Council (MRC) COIN trial, the epidermal growth factor receptor (EGFR)-targeted antibody cetuximab was added to…”
Get full text

Intermittent chemotherapy plus either intermittent or continuous cetuximab for first-line treatment of patients with KRAS wild-type advanced colorectal cancer (COIN-B): a randomised phase 2 trial by Wasan, Harpreet, MD, Meade, Angela M, Dr, Adams, Richard, MD, Wilson, Richard, MD, Pugh, Cheryl, BSc, Fisher, David, MSc, Sydes, Benjamin, Madi, Ayman, MD, Sizer, Bruce, MB, Lowdell, Charles, FRCP, Middleton, Gary, MD, Butler, Rachel, BSc, Kaplan, Richard, Prof, Maughan, Tim, Prof

“…Summary Background Advanced colorectal cancer is treated with a combination of cytotoxic drugs and targeted treatments. However, how best to minimise the time…”
Get full text

Intermittent versus continuous oxaliplatin and fluoropyrimidine combination chemotherapy for first-line treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial by Adams, Richard A, FRCP, Meade, Angela M, DPhil, Seymour, Matthew T, Prof, Wilson, Richard H, MD, Madi, Ayman, MRCP, Fisher, David, MSc, Kenny, Sarah L, MSc, Kay, Edward, BA, Hodgkinson, Elizabeth, BPharm, Pope, Malcolm, Rogers, Penny, BSc, Wasan, Harpreet, FRCP, Falk, Stephen, MD, Gollins, Simon, DPhil, Hickish, Tamas, MD, Bessell, Eric M, PhD, Propper, David, MD, Kennedy, M John, MD, Kaplan, Richard, Prof, Maughan, Timothy S, Prof

“…Summary Background When cure is impossible, cancer treatment should focus on both length and quality of life. Maximisation of time without toxic effects could…”
Get full text

Different strategies of sequential and combination chemotherapy for patients with poor prognosis advanced colorectal cancer (MRC FOCUS): a randomised controlled trial by Seymour, Matthew T, Prof, Maughan, Timothy S, Prof, Ledermann, Jonathan A, Prof, Topham, Clare, MD, James, Roger, Prof, Gwyther, Stephen J, MBBS, Smith, David B, MD, Shepherd, Stephen, MD, Maraveyas, Anthony, PhD, Ferry, David R, Prof, Meade, Angela M, PhD, Thompson, Lindsay, MSc, Griffiths, Gareth O, MSc, Parmar, Mahesh KB, Prof, Stephens, Richard J

“…Summary Background In the non-curative setting, the sequence in which anticancer agents are used, singly or in combination, may be important if patients are to…”
Get full text

Randomized controlled pilot trial of naloxone‐on‐release to prevent post‐prison opioid overdose deaths by Parmar, Mahesh K. B., Strang, John, Choo, Louise, Meade, Angela M., Bird, Sheila M.

“…Background and Aims Naloxone is an opioid antagonist used for emergency resuscitation following opioid overdose. Prisoners with a history of heroin injection…”
Get full text

Optimal maintenance strategy following FOLFOX plus anti-EGFR induction therapy in patients with RAS wild type metastatic colorectal cancer: An individual patient data pooled analysis of randomised clinical trials by Raimondi, Alessandra, Nichetti, Federico, Stahler, Arndt, Wasan, Harpreet S., Aranda, Enrique, Randon, Giovanni, Kurreck, Annika, Meade, Angela M., Díaz-Rubio, Eduardo, Niger, Monica, Stintzing, Sebastian, Palermo, Federica, Trarbach, Tanja, Prisciandaro, Michele, Sommerhäuser, Greta, Fisher, David, Morano, Federica, Pietrantonio, Filippo, Modest, Dominik P.

“…Anti-EGFR antibodies plus doublet chemotherapy is the standard of care in RAS/BRAF wild-type metastatic colorectal cancer (mCRC). No phase-3 level of evidence…”
Get full text

Predictive Biomarkers of Chemotherapy Efficacy in Colorectal Cancer: Results From the UK MRC FOCUS Trial by Braun, Michael S, Richman, Susan D, Quirke, Philip, Daly, Catherine, Adlard, Julian W, Elliott, Faye, Barrett, Jennifer H, Selby, Peter, Meade, Angela M, Stephens, Richard J, Parmar, Mahesh K B, Seymour, Matthew T

“…Candidate predictive biomarkers for irinotecan and oxaliplatin were assessed in 1,628 patients in Fluorouracil, Oxaliplatin, CPT-11: Use and Sequencing…”
Get full text

Adding new experimental arms to randomised clinical trials: Impact on error rates by Choodari-Oskooei, Babak, Bratton, Daniel J, Gannon, Melissa R, Meade, Angela M, Sydes, Matthew R, Parmar, Mahesh KB

“…Background: Experimental treatments pass through various stages of development. If a treatment passes through early-phase experiments, the investigators may…”
Get full text

Pharmacogenetic analyses of 2183 patients with advanced colorectal cancer; potential role for common dihydropyrimidine dehydrogenase variants in toxicity to chemotherapy by Madi, Ayman, Fisher, David, Maughan, Timothy S., Colley, James P., Meade, Angela M., Maynard, Julie, Humphreys, Vikki, Wasan, Harpreet, Adams, Richard A., Idziaszczyk, Shelley, Harris, Rebecca, Kaplan, Richard S., Cheadle, Jeremy P.

“…Inherited genetic variants may influence response to, and side-effects from, chemotherapy. We sought to generate a comprehensive inherited pharmacogenetic…”
Get full text

Clarification re naloxone administered to study subject versus other overdose victim in the N‐ALIVE pilot randomized trial by Parmar, Mahesh K. B., Strang, John, Choo, Louise, Meade, Angela M., Bird, Sheila M.

Get full text

Association of Molecular Markers With Toxicity Outcomes in a Randomized Trial of Chemotherapy for Advanced Colorectal Cancer: The FOCUS Trial by BRAUN, Michael S, RICHMAN, Susan D, THOMPSON, Lindsay, DALY, Catherine L, MEADE, Angela M, ADLARD, Julian W, ALLAN, James M, PARMAR, Mahesh K. B, QUIRKE, Philip, SEYMOUR, Matthew T

“…Predicting efficacy and toxicity could potentially allow individualization of cancer therapy. We investigated putative pharmacogenetic markers of chemotherapy…”
Get full text

Does anti-EGFR therapy improve outcome in advanced colorectal cancer? A systematic review and meta-analysis by Vale, Claire L, Tierney, Jayne F, Fisher, David, Adams, Richard A, Kaplan, Richard, Maughan, Timothy S, Parmar, Mahesh K.B, Meade, Angela M

“…Abstract Background Randomised controlled trials (RCTs) of anti-EGFR monoclonal antibodies (MAb) in patients with advanced colorectal cancer (aCRC) have…”
Get full text

Choosing the right strategy based on individualized treatment effect predictions: combination versus sequential chemotherapy in patients with metastatic colorectal cancer by Kwakman, Johannes J M, van Kruijsdijk, Rob C M, Elias, Sjoerd G, Seymour, Matthew T, Meade, Angela M, Visseren, Frank L J, Punt, Cornelis J A, Koopman, Miriam

“…Translating results from randomized trials to individual patients is challenging, since treatment effects may vary due to heterogeneous prognostic…”
Get more information

Comprehensive pharmacogenetic profiling of the epidermal growth factor receptor pathway for biomarkers of response to, and toxicity from, cetuximab by Madi, Ayman, Fisher, David, Maughan, Timothy S, Colley, James P, Meade, Angela M, Tejpar, Sabine, Van den Bosch, Ben, Maynard, Julie, Humphreys, Vikki, Wasan, Harpreet, Adams, Richard A, Idziaszczyk, Shelley, Harris, Rebecca, Kaplan, Richard S, Cheadle, Jeremy P

“…Somatic mutations in the epidermal growth factor receptor (EGFR) intracellular signalling pathways predict non-response to cetuximab in the treatment of…”
Get more information

Common variation at 2q22.3 (ZEB2) influences the risk of renal cancer by Henrion, Marc, Frampton, Matthew, Scelo, Ghislaine, Purdue, Mark, Ye, Yuanqing, Broderick, Peter, Ritchie, Alastair, Kaplan, Richard, Meade, Angela, McKay, James, Johansson, Mattias, Lathrop, Mark, Larkin, James, Rothman, Nathaniel, Wang, Zhaoming, Chow, Wong-Ho, Stevens, Victoria L, Ryan Diver, W, Gapstur, Susan M, Albanes, Demetrius, Virtamo, Jarmo, Wu, Xifeng, Brennan, Paul, Chanock, Stephen, Eisen, Timothy, Houlston, Richard S

“…Genome-wide association studies (GWASs) of renal cell cancer (RCC) have identified four susceptibility loci thus far. To identify an additional RCC common…”
Get full text

Adapting the design of the ongoing RAMPART trial in response to external evidence: An example for trials which take many years to run and report by Meade, Angela, Frangou, Elena, Choodari-Oskooei, Babak, Larkin, James, Powles, Tom, Stewart, Grant D., Albiges, Laurence, Bex, Axel, Choueiri, Toni K., Davis, Ian D., Eisen, Tim, Fielding, Alison, Gedye, Craig, Harrison, David J., Kaplan, Rick, Mulhere, Salena, Nathan, Paul, Patel, Grisma, Patel, Jay, Plant, Hannah, Ritchie, Alastair, Rush, Hannah, Shakeshaft, Clare, Stockler, Martin R., Suarez, Cristina, Thompson, Jemima, Thorogood, Nat, Venugopal, Balaji, Parmar, Mahesh K.B.

“…Clinical trials to establish the efficacy of new agents in the adjuvant cancer setting typically take many years to complete. During that time, external…”
Get full text

Common variation at 1q24.1 (ALDH9A1) is a potential risk factor for renal cancer by Henrion, Marc Y R, Purdue, Mark P, Scelo, Ghislaine, Broderick, Peter, Frampton, Matthew, Ritchie, Alastair, Meade, Angela, Li, Peng, McKay, James, Johansson, Mattias, Lathrop, Mark, Larkin, James, Rothman, Nathaniel, Wang, Zhaoming, Chow, Wong-Ho, Stevens, Victoria L, Diver, W Ryan, Albanes, Demetrius, Virtamo, Jarmo, Brennan, Paul, Eisen, Timothy, Chanock, Stephen, Houlston, Richard S

“…So far six susceptibility loci for renal cell carcinoma (RCC) have been discovered by genome-wide association studies (GWAS). To identify additional RCC common…”
Get full text

External data required timely response by the Trial Steering-Data Monitoring Committee for the NALoxone InVEstigation (N-ALIVE) pilot trial by Bird, Sheila M, Strang, John, Ashby, Deborah, Podmore, John, Robertson, J. Roy, Welch, Sarah, Meade, Angela M, Parmar, Mahesh K.B

“…Abstract The prison-based N-ALIVE pilot trial had undertaken to notify the Research Ethics Committee and participants if we had reason to believe that the…”
Get full text

The Cost-Effectiveness of Different Chemotherapy Strategies for Patients with Poor Prognosis Advanced Colorectal Cancer (MRC FOCUS) by Manca, Andrea, MSc, PhD, Asseburg, Christian, PhD, Bravo Vergel, Yolanda, MSc, Seymour, Matt T., MB, BS, Meade, Angela, PhD, Stephens, Richard, PhD, Parmar, Mahesh, PhD, Sculpher, Mark J., MSc, PhD

“…Abstract Objectives To assess the value for money of alternative chemotherapy strategies for managing advanced colorectal cancer using irinotecan or…”
Get full text